Natco

Lupin recalled 26,352 bottles of Rifampin capsules, used in the treatment of tuberculosis

Natco Q1 PAT seen up 36.2% YoY to Rs 436.5 cr: Nirmal Bang

Net Sales are expected to increase by 35.1 percent Y-o-Y (up 33.1 percent Q-o-Q) to Rs 1,195.4 crore, according to Nirmal Bang.

Natco Pharma surges 3% on positive outlook

The volumes were also positive as 11 lakh shares changed hands against the one-month daily traded average of 9 lakh

Revlimid is shaping up to be a meaningfully large opportunity for India’s pharma universe: Nithya Balasubramanian

Apart from the drug used as part of the treatment for a type of blood cancer, other medicines going off-patent will boost the prospects of companies like Dr Reddy’s and Cipla, the healthcare analyst at Sanford Bernstein said.

Johnson & Johnson, Momenta Pharma file patent infringement lawsuit against Natco, Mylan in US

Johnson & Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate injection, Natco said in a regulatory filing.

Natco gets CDSCO nod for emergency use of Baricitinib tablets for COVID-19 treatment

CDSCO is responsible for approval of drugs, conduct of clinical trials, laying down the standards for drugs, control over the quality of imported drugs in the country and coordination of the activities of state drug control organisations.

Natco Q3 PAT may dip 24% YoY to Rs. 165 cr: Sharekhan

Net Sales are expected to decrease by 5 percent Y-o-Y (down 1.8 percent Q-o-Q) to Rs. 534 crore, according to Sharekhan.

Natco Q2 PAT seen up 78.6% YoY to Rs. 150 cr: Sharekhan

Net Sales are expected to increase by 20 percent Y-o-Y (down 4.9 percent Q-o-Q) to Rs. 512 crore, according to Sharekhan.

Stocks in the news: Hindalco, Inox Leisure, Tata Motors, Hero Motocorp, Quess Corp

Hindalco | Inox Leisure | Tata Motors | Hero Motocorp | SML Isuzu | Quess Corp and Vakrangee are stocks, which are in news today.

Bayer's plea against compulsory licensing hits hurdle

A division bench of the Bombay HC, headed by Justice Oka, refused Bayer‘s plea to place the matter before the court for urgent hearing. In a brief order passed today, the division bench cited several pending cases and disregarded the urgency cited by Bayer.

Stocks in news: Asian Paints, 3M India, IFCI, Natco, Bharti

Asian Paints | Lloyds Steel | 3M India | PNB | IFCI | SAIL | Natco Pharma | M&M and Bharti Airtel are stocks, which are in the news today.

Naren of ICICI Prudential MF does things pre-mortem

Rigorous research has been the backbone of ICICI Prudential's decisions to go against the mutual fund tide, and emerge successful.

Bayer fights courts for Nexavar as cheaper rivals take over

German drugmaker Bayer may be fighting it out in the courtroom to defend its patent rights on cancer drug Nexavar. But out in the market, it's already lost considerable market share to cheaper variants from Cipla and Natco.

Developing world supports India's compulsory licence policy

CNBC-TV18's Archana Shukla reports that India's grant of a compulsory licence to Natco for Bayer's kidney-cancer drug Nexavar has sent shockwaves across the globe

Experts divided over compulsory drug licence dispute

By granting compulsory license to Natco for Bayer's kidney cancer drug Nexavar, the Indian government has opened a legal can of worms, reports CNBC-TV18's Archana Shukla.

Compulsory license forces MNC pharma to rework India plan

Compulsory license granted to Natco has left the Indian pharma industry with a hard choice to make - cut prices, or quit selling the drug. To counter this drug-makers are changing strategies, reports CNBC-TV18's Archana Shukla.

Natco win: Deterrent for FDI?

By: Rahul Dhote & Mita Sheikh, Krishna & Saurastri

Stocks in news: GVK, Rel Infra, M&M, Gitanjali Gems, Natco

Gitanjali Gems | Natco | TIL | GVK | Reliance Infrastructure | TCS | Mahindra Composites | Gujarat Pipavav | Punj Lloyd | SAIL and M&M are stocks, which are in the news today.